WntResearch provides update on the clinical development of the drug candidate Foxy-5
WntResearch today announced that the last of totally 12 patients has been included in the dose-ranging part of a Phase 1b study with the drug candidate Foxy-5. This is expected to enable a decision this spring on the dose level for the planned Phase 2 study. Furthermore, a retrospective tumor sample study, whose results will be important in defining the continued development route for Foxy-5, has been initiated.In preclinical models, Foxy-5 has been shown to reduce tumor cell mobility, thus preventing the emergence of metastases. In the ongoing Phase 1b study, the drug candidate is